protein

Human Fibroblast Growth Factor 10 Recombinant

MBS553029

0.025 mg

220 USD

Recombinant Protein

Human Fibroblast Growth Factor 10 Recombinant

Fibroblast Growth Factor 10

FGF10; fgf-10; fibroblast growth factor; kgf2; kgf-2

fibroblast growth factor 10; Fibroblast growth factor 10; Keratinocyte growth factor 2

FGF-10

FGF10; FGF-10

FGF10_HUMAN

E Coli

208

MWKWILTHCA SAFPHLPGCC CCCFLLLFLV SSVPVTCQAL GQDMVSPEAT NSSSSSFSSP SSAGRHVRSY NHLQGDVRWR KLFSFTKYFL KIEKNGKVSG TKKENCPYSI LEITSVEIGV VAVKAINSNY YLAMNKKGKL YGSKEFNNDC KLKERIEENG YNTYASFNWQ HNGRQMYVAL NGKGAPRRGQ KTRRKNTSAH FLPMVVHS

>96%, as determined by SDS-PAGE and HPLC

Recombinant FGF10 was lyophilized from 0.2 um filtered PBS solution, pH 7.0.

The lyophilized protein is stable for at least 2 years from date of receipt at -20 degree C. Upon reconstitution, this cytokine can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

Domain: HBGF/IL1. Host Note: Optimized DNA sequence encoding Human Fibroblast Growth Factor-10 mature chain was expressed in Escherichia Coli.

Endotoxin: Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug). Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. Molecular Weight Note: Native human FGF10 is generated by the proteolytic removal of the signal peptide. and propeptide, this molecule has a calculated molecular mass of approximately 19 kDa. Recombinant Fibroblast Growth Factor 10 is a disulfide-linked monomer protein consisting of 170 amino acid residue subunits, and migrates as an approximately 19 kDa protein under non-reducing and reducing conditions in SDS-PAGE.

Cytokines

FGF-10 is involved in the initial budding as well as the continuous outgrowth of vertebrate limbs, FGF10 mRNA is expressed preferentially in neurons but not in glial cells and may have a distinct role in the brain.

a new FGF10 mutation in the mouse leads to atrophy of the harderian gland and slit-eye phenotype in heterozygotes: a novel model for dry-eye disease? . Invest. Ophthalmol. Vis. Sci., Sep 2009; 50: 4311 - 4318. the homeodomain transcription factor barx2 is required for normal lacrimal gland development and cooperates with FGF10 in regulation of branching morphogenesis . Invest. Ophthalmol. Vis. Sci., Apr 2009; 50: 4236. progesterone regulates FGF10 , met, igfbp1, and igfbp3 in the endometrium of the ovine uterus . Biol Reprod, Dec 2008; 79: 1226 - 1236. cystic adenomatoid malformations are induced by localized FGF10 overexpression in fetal rat lung . Am. J. Respir. Cell Mol. Biol., Sep 2008; 39: 346 - 355. specific heparan sulfate structures modulate FGF10 -mediated submandibular gland epithelial morphogenesis and differentiation . J. Biol. Chem., Apr 2008; 283: 9308 - 9317.

4758360

NP_004456.1

NM_004465.1

O15520

23,436 Da

Downstream Signaling Of Activated FGFR Pathway 160957!!FGFR Ligand Binding And Activation Pathway 106344!!FGFR1 Ligand Binding And Activation Pathway 106345!!FGFR1b Ligand Binding And Activation Pathway 106346!!FGFR2 Ligand Binding And Activation Pathway 106349!!FGFR2b Ligand Binding And Activation Pathway 106350!!FRS2-mediated Cascade Pathway 160958!!Heart Development Pathway 198802!!IRS-mediated Signalling Pathway 106426!!IRS-related Events Pathway 106424

Function: Plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. Required for normal branching morphogenesis. May play a role in wound healing. Ref.8. Subunit structure: Interacts with FGFR1 and FGFR2. Interacts with FGFBP1. Ref.7 Ref.8. Subcellular location: Secreted . Potential. Involvement in disease: Aplasia of lacrimal and salivary glands (ALSG) [MIM:180920]: A rare condition characterized by dry conjunctival mucosae, irritable eyes, epiphora (constant tearing), and xerostomia (dryness of the mouth), which increases risk of dental erosion, dental caries, periodontal disease, and oral infections. ALSG has variable expressivity, and affected individuals may have aplasia or hypoplasia of the lacrimal, parotid, submandibular, and sublingual glands and absence of the lacrimal puncta.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.11Lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]: An autosomal dominant ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Lacrimo-auriculo-dento-digital syndrome is characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.12 Ref.13. Sequence similarities: Belongs to the heparin-binding growth factors family.

0.025 mg

220 USD